<DOC>
	<DOC>NCT00530504</DOC>
	<brief_summary>The purposes of this study are: 1. To provide additional safety and effectiveness information on the commercial use of Protégé™ GPS™ and Protégé™ RX Carotid Stent Systems and the SpiderFX™ Embolic Protection Device. 2. To evaluate rare and unanticipated adverse events. 3. To evaluate the physician level of experience with carotid artery stenting procedures with adverse event rates.</brief_summary>
	<brief_title>Carotid Revascularization With ev3 Arterial Technology Evolution Post Approval Study</brief_title>
	<detailed_description />
	<mesh_term>Carotid Artery Diseases</mesh_term>
	<criteria>18 years and above Informed consent Intent to use the PROTÉGÉ™ GPS™ and PROTÉGÉ™ RX and SpiderFX™ to treat carotid artery disease per Instructions for Use Meet Instruction for Use (IFU)/ Centers for Medicare &amp; Medicaid Services (CMS)defined anatomical or clinical high risk criteria Subjects with contraindications as outlined in the Instructions for Use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Carotid Artery Disease</keyword>
	<keyword>Embolic Protection</keyword>
</DOC>